Theralase Technologies Inc.

Symbol: TSXV: TLT OTCQB: TLTFF
Market Cap: 65M
Purpose Financing

Sector: Technology
Summary:
  • Theralase┬« is focused on providing the next standard of care treatment for bladder cancer. The 10th most common cancer in the world (6th in men).
  • Theralase┬« combines a patented light-sensitive drug and proprietary laser system that has the ability to destroy cancer directly in the bladder.
  • Theralase┬« has enrolled and provided the primary study treatment for 59 / 100 patients in a FDA Phase II registration clinical study, that if successful will grant Theralase commercial access to cancer markets worth between an estimated $1 to $7 B annually.